Absence of the CHEK2 c.1100delC mutation in familial breast and ovarian cancer in Colombia: a case-control study
Background: BRCA1 and BRCA2 have been identified as high-penetrance breast cancer predisposition genes, but they only account for a small fraction of the inherited component of breast cancer. To explain the remaining cases, a polygenic model with a large number of low-to moderate-penetrance genes ha...
- Autores:
-
Rivera Herrera, Ana Lucia
Cifuentes Cardona, Laura Fernanda
Gil Vera, J. A.
Barreto, Guillermo
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2023
- Institución:
- Universidad Cooperativa de Colombia
- Repositorio:
- Repositorio UCC
- Idioma:
- OAI Identifier:
- oai:repository.ucc.edu.co:20.500.12494/50416
- Acceso en línea:
- https://doi.org/10.12688/f1000research.13368.1
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85062855251&doi=10.12688%2ff1000research.13368.1&partnerID=40&md5=8f6e11e47f8c350bfe93dda0ec915e52
https://hdl.handle.net/20.500.12494/50416
- Palabra clave:
- ADULT
AGE
ALLELE SPECIFIC POLYMERASE CHAIN REACTION
ARTICLE
BREAST CANCER
CANCER RISK
CANCER SCREENING
CANCER SUSCEPTIBILITY
CLINICAL FEATURE
COHORT ANALYSIS
COLOMBIA
CONTROLLED STUDY
CROSS-SECTIONAL STUDY
CHECKPOINT KINASE 2
CHEK2 GENE
FEMALE
GENE FUNCTION
GENE MUTATION
GENETIC SCREENING
GENOTYPE
HETEROZYGOTE
HOMOZYGOTE
HUMAN
MAJOR CLINICAL STUDY
OVARY CANCER
RISK FACTOR
SEX
SOCIAL STATUS
- Rights
- openAccess
- License
- http://purl.org/coar/access_right/c_abf2
| Summary: | Background: BRCA1 and BRCA2 have been identified as high-penetrance breast cancer predisposition genes, but they only account for a small fraction of the inherited component of breast cancer. To explain the remaining cases, a polygenic model with a large number of low-to moderate-penetrance genes have been proposed; one of these, is the CHEK2 gene (Checkpoint Kinase 2). The objective of this study was to determine the role of the CHEK2 gene, specifically the c.1100delC mutation in familial breast cancer susceptibility in Colombian patients. Methods: We screened 131 high-risk breast and/or ovarian cancer patients (negative for mutations in BRCA1 and BRCA2) and 131 controls for the germline mutation CHEK2 c.1100delC by allele-specific PCR. Results: None of the cases or controls showed the CHEK2 c.1100delC mutation, neither as a homozygote nor as a heterozygote. Conclusions: Our results suggest that the CHEK2 c.1100delC mutation is not a risk factor for genetic susceptibility to familial breast or ovarian cancer in the Colombian population. The absence of the CHEK2 c.1100delC mutation in our population show the importance of considering ethnic background before offering a genetic test. © 2018 Rivera-Herrera AL et al. |
|---|